(Q37038352)

17 August 2017

1 reference

title

Outpatient chemotherapy plus radiotherapy in sarcomas: improving cancer control with radiosensitizing agents (English)

1 reference

Adaptive radiation therapy

17 August 2017

main subject

0 references

1 reference

Pete Anderson

1

1 reference

17 August 2017

Dolly Aguilera

series ordinal

2

1 reference

17 August 2017

Margaret Pearson

series ordinal

3

1 reference

17 August 2017

Shaio Woo

series ordinal

4

1 reference

17 August 2017

language of work or name

1 reference

1 January 2008

1 reference

17 August 2017

1 reference

17 August 2017

volume

15

1 reference

17 August 2017

issue

1

1 reference

17 August 2017

page(s)

38-46

1 reference

Chemoradiation for malignant epithelial tumors.

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

The role of radiation in retroperitoneal sarcomas: a surgical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Evidence-based recommendations for local therapy for soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Radiotherapy for local control of osteosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Radiation therapy for control of soft-tissue sarcomas resected with positive margins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Advanced-technology radiation therapy in the management of bone and soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Preoperative chemotherapy and split-course radiation therapy for patients with localized soft tissue sarcomas: home run, base hit, or strike out?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Mechanistic aspects of the cytotoxic activity of glufosfamide, a new tumour therapeutic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Insights into oxazaphosphorine resistance and possible approaches to its circumvention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Ifosfamide in the adjuvant therapy of soft tissue sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Advances in chemotherapy for patients with extremity soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Emerging treatments for soft tissue sarcoma of adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Ifosfamide clinical pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Pharmacology of Ifosfamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Cyclophosphamide cystitis—Identification of acrolein as the causative agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Novel therapeutic approaches in pediatric and young adult sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Ifosfamide: pharmacokinetic properties for central nervous system metastasis prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Methylene blue reversal of ifosfamide-related encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Methylene blue for management of Ifosfamide-induced encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Evaluating risk factors for the development of ifosfamide encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Comparative preclinical toxicology and pharmacology of isophosphoramide mustard, the active metabolite of ifosfamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Reversal of resistance to oxazaphosphorines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Treatment of Ewing sarcoma family of tumors: current status and outlook for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Ewing's sarcoma family of tumors: current management

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Temozolomide: a novel oral alkylating agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Temozolomide: realizing the promise and potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Advances in the treatment of primary brain tumors: dawn of a new era?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Treatment of metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and improves quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Successful treatment of a chemoresistant tumor with temozolomide in an adult patient: report of a recurrent intracranial mesenchymal chondrosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Whole brain irradiation and temozolomide based chemotherapy in melanoma brain metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

The evolution of chemoradiation for glioblastoma: a modern success story

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Irinotecan plus temozolomide for relapsed or refractory neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Early lymphocyte recovery as a prognostic indicator for high-risk Ewing sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Pancreatic cancer: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Overview of gemcitabine activity in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Gemcitabine and radiation therapy in non-small cell lung cancer: state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Systemic chemotherapy in the management of malignant peritoneal mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Role of gemcitabine in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Role of chemotherapy in patients with soft tissue sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Recent advances in systemic therapy of soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Gemcitabine and radiosensitization in human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Enhancement of radiation-induced regrowth delay by gemcitabine in a human tumor xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Biologic basis for combining drugs with radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Combined modality therapy of gemcitabine and radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Increased expression of pro-inflammatory cytokines as a cause of lung toxicity after combined treatment with gemcitabine and thoracic irradiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

The role of preoperative radiotherapy in nonmetastatic high-grade osteosarcoma of the extremities for limb-sparing surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric Oncology Group Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

21 January 2018

Metastatic osteosarcoma

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Samarium for osteoblastic bone metastases and osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Improving outcomes in difficult bone cancers using multimodality therapy, including radiation: physician and nursing perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

Preoperative chemoradiation and flap reconstruction provide high local control and low wound complication rates for patients undergoing limb salvage surgery for upper extremity tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500105

10.1177/107327480801500105

21 January 2018

Identifiers

DOI

0 references

1 reference